UNION therapeutics announces positive topline results from the OSIRIS investigator-initiated proof-of-concept study of oral orismilast in patients with hidradenitis suppurativa
· Study demonstrates clinically relevant improvements in patients with hidradenitis suppurativa (HS) receiving 16 weeks of treatment with oral orismilast · Study supports the dose-finding results from the recent IASOS Phase 2b study of oral orismilast in psoriasis · Orismilast has been granted a Fast Track designation by the FDA for HS, and UNION plans to seek regulatory advice on the design of the pivotal study program · Orismilast is a high potency, next-generation PDE4 inhibitor with broad anti-inflammatory properties also in development for oral treatment of atopic dermatitis (